Compare COO & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COO | RDY |
|---|---|---|
| Founded | 1980 | 1984 |
| Country | United States | India |
| Employees | N/A | 27527 |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.9B |
| IPO Year | 1994 | 2001 |
| Metric | COO | RDY |
|---|---|---|
| Price | $68.77 | $14.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $90.18 | $16.90 |
| AVG Volume (30 Days) | ★ 3.5M | 1.6M |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $2,532,800,000.00 | N/A |
| Revenue This Year | $6.66 | $7.72 |
| Revenue Next Year | $5.18 | $3.50 |
| P/E Ratio | $245.00 | ★ $18.67 |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $58.89 | $12.19 |
| 52 Week High | $89.83 | $15.25 |
| Indicator | COO | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 63.74 | 71.46 |
| Support Level | $67.91 | $13.80 |
| Resistance Level | $69.74 | $14.93 |
| Average True Range (ATR) | 1.82 | 0.23 |
| MACD | 0.24 | 0.13 |
| Stochastic Oscillator | 97.30 | 98.97 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.